138 results about "Postoperative adhesion" patented technology

An implantable prosthesis for an anatomical defect, such as a tissue or muscle defect, that promotes tissue or muscle growth into the prosthesis and subsequently strengthens the area of the defect. At least one pocket and preferably two concentric pockets may be provided to aid with manipulating the prosthesis. Where two pockets are used, a barrier or partition exists between the pockets and the outer pocket allows manipulation of the outer periphery. The incidence of postoperative adhesions between a portion of the prosthesis and tissue, muscle or organs may be minimized with the use of a barrier layer. Reinforcing members may be attached to portions of the prosthesis to aid in positioning and deployment in the area of desired coverage without rendering the prosthesis unduly difficult to implant or uncomfortable for the patient. Typically, two concentric members are employed. Further, the prosthesis is constructed to allow it to be provisionally held in place at desired locations by openings in the pockets that allow access for a stapler or sewing device.

A composite prosthesis and method for limiting the incidence of postoperative adhesions. The composite includes a non-inflammatory or coated mesh and a barrier material which prevents exposure of tissue elsewhere in the body to tissue covered by the composite prosthesis. The barrier material is absorbable which allows tissue through-growth and localization of the composite prosthetic. In use, the composite prosthesis is positioned over the tissue defect and may be positioned with the barrier material oriented against the tissue defect or repair site.

The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering Pemirolast, or an analog thereof, directly to tissue surfaces in the body cavity in amounts and under conditions effective to inhibit formation of adhesions, and to delivery vehicles and compositions suitable for use for local, non-systemic administration of a drug to the body and directly to tissue within a body cavity having been subjected to a surgical procedure.

The invention relates to a preparation method of an anti-adhesion fibrous membrane with a hemostatic function. Two or three organic polymer solutions are mixed, composite fiber materials in a multi-nozzle electrostatic spinning mode are prepared, and the anti-adhesion fibrous membrane is prepared by treating the composite fiber materials in a crosslinking mode. According to the composite fiber materials prepared by the preparation method, two or three organic polymer solutions are mixed and then processed in a multi-nozzle electrostatic spinning mode by using the electrostatic spinning technology, due to the fact that organic polymer materials is adjusted, the mechanical strength of the organic polymer materials is improved, and meanwhile through crossing treatment, an anti-adhesion material which forms gels on the surface after contacting with blood is prepared, a physical hemostasis effect is achieved, and meanwhile the anti-adhesion fibrous effect is achieved. The preparation method of the anti-adhesion fibrous membrane preparation method with the hemostatic function is simple in technic, easy to operate and low in cost, enables the functions of hemostasis and postoperative adhesion prevention to be achieved, and has wide application prospect in surgical field.

The invention provides an anti-adhesion biological membrane and a preparation method thereof. The anti-adhesion biological membrane is a dry membrane which is formed by SIS (styrene isoprene styrene block copolymer) as a support material, compound hyaluronic acid, functional proteins and anti-inflammotary medicines. The anti-adhesion biological membrane is semi-transparent from light white to faint yellow. The thickness of the anti-adhesion biological membrane is 0.01-0.5mm. Compared with the prior art, the anti-adhesion biological membrane has very good biocompatibility, good physical barrier anti-adhesion effect and the effects of resisting inflammatory, stopping bleeding and promoting fiber degradation. The effects of the anti-adhesion biological membrane are obviously superior to those of existing anti-adhesion biological membrane products. Animal experiments prove that the effective rate of the anti-adhesion biological membrane prepared by the method for preventing the adhesion after abdominal surgery reaches above 90%, the effective rate for preventing the adhesion after pelvic cavity surgery reaches above 80%, and the effective rate for preventing the adhesion after tendon surgery reaches above 70%.

An implantable prosthesis is provided for repairing an anatomical defect, such as a tissue or muscle defect, that promotes tissue of muscle ingrowth into the prosthesis and subsequently strengthens the area of the defect. The prosthesis is easy to manipulate and may be designed to minimize the incidence of postoperative adhesions between a portion of the prosthesis and surrounding tissue or organs. The prosthesis may include one or more layers of biologically compatible material that is suitable for repairing a defect. The prosthesis may include a support assembly to facilitate manipulation and deployment of the prosthesis. The support assembly may include a stiffening member that is surrounded by material that separates the stiffening member from the layer of material. The stiffening member may be located in a sleeve of material, such as mesh fabric. The stiffening member may be formed from a resorbable material.

The invention relates to a medical anti-adhesion agent which comprises carboxymethyl chitosan and equilibrium liquid. The solvent of the equilibrium liquid is water for injection, and the solute of the equilibrium liquid comprises sodium chloride and monopotassium phosphate. The anti-adhesion agent comprises, in weight percent, 0.1%-10% of carboxymethyl chitosan, preferably 0.2%-5% of carboxymethyl chitosan, more preferably 0.5%-4.0% of carboxymethyl chitosan, 0.5%-1% of sodium chloride and 0.1%-2% of monopotassium phosphate. The invention further relates to a method for preparing the anti-adhesion agent. The anti-adhesion agent can be in the form of gel or flushing fluid, is used for preventing postoperative adhesion in general surgery department and gynecology and obstetrics, and can also be used for surgical or trauma flushing. The anti-adhesion agent is non-toxic, non-irritant, biodegradable and free of sensitization, and has fine antibacterial activity and anti-adhesion effects.

The invention belongs to the technical field of biomedical materials, and particularly relates to a preparation method and an application of a sustained-release system of anti-inflammatory medicaments and growth factors; a nanofiber drug loaded film prepared by the method is applicable to postoperative adhesion prevention and inflammation resistance, and skin tissue engineering stents. As a postoperative adhesion preventing film, the product has biodegradability and good biocompatibility, and can prevent postoperative inflammatory response through the controlled release of anti-inflammatory medicaments; meanwhile, through the combination of the medicaments with growth factors, the product can be used in skin tissue engineering, not only prevents inflammatory response at affected sites, but also releases growth factors to promote the regeneration and healing of skin cells. The nanofiber drug loaded film preparation method has a simple process and good controllability, and has wide application prospects in the fields of postoperative adhesion prevention and inflammation resistance, as well as skin tissue engineering.

Polyurea systems comprising: (a) an amino-functional aspartic ester of the general formula (I)

wherein X represents an n-valent organic radical derived from a corresponding n-functional primary amine X(NH₂)_n, R₁ and R₂ each independently represent an organic radical having no Zerevitinov active hydrogens and n represents an integer of at least 2; and (b) an isocyanate functional prepolymer having a residual monomer content of less than 1% by weight, the prepolymer prepared by reacting: (b1) an aliphatic isocyante; and (b2) a polyol component having a number average molecular weight of ≧400 g/mol and an average OH functionality of 2 to 6, wherein the polyol component comprises one or more constituents selected from the group consisting of polyester polyols, polyester-polyether polyols and mixtures thereof; processes for making the same; postoperative adhesions barriers prepared therewith and dispensing systems for such polyurea systems.

The present invention provides a tissue adhesion prevention material preparable at an affected area at the time of surgical procedure by producing a three-dimensional polymeric structure having a flexible structure and high solute permeability in a medium comprising water as the main component under mild conditions appropriate for body tissue components (i.e., at ordinary temperature and pressure) without conducting a chemical reaction or employing a physical procedure such as heating or light or radiation irradiation. This makes it possible to provide a tissue adhesion prevention material and a joint contracture prevention materials, which can effectively prevent postoperative adhesion of a tissue in the affected area to the surrounding tissue and contracture of the movable part of a joint.

The tissue adhesion prevention material and/or the joint contracture prevention material of the present invention comprise, as the main component, a composition comprising a compound having a polyvalent hydroxyl group and a polymer containing phosphorylcholine groups and phenylboronic acid groups.

A post operation adhesion proof carboxymethyl chitin membrane characterizing in containing carboxymethyl chitin and cross linking agent or chitosan is provided. The weight ratio of carboxymethyl chitin with cross linking agent is 100:0.1í½0.5, while the weight ratio of carboxymethyl chitin with chitosan is 100:10í½1000. The preparing process: carboxy methylating chitin to carboxymethyl chitin, combining with cross linking agent or chitosan to prepare carboxy methylating chitin water soluble collagen solution or acid solution, preparing to carboxy methylating chitin dry membrane, flushing and drying. The adhesion proof membrane provided by the invention has favorable tissue compatibility, favorable adhesion with body wound surface, rapid degradation rate, in addition, the degradation product can be absorbed and utilized by body without adverse reaction.

The invention provides a biodegradable textile fiber adhesive-bonded fabric to prevent adhesion after the operation and its preparing method, which belongs to the domain of medical article, and relates to the preparation of a nanometre-sized fiber adhesive-bonded fabric and the application as the anti-block film after the operation. The said adhesive-bonded fabric is prepared by adopting electrostatic spinning method, which includes preparing spin dope, dissolving the aliphatic polyester in the flux and mixing intimately to prepare the aliphatic polyester spin dope. The used flux of the spin dope can be one or compound system of two of carrene, chloroform, acetone, acetylene tetrachloride,acetic acid dimethylamide. Secondarily on the electrostatic spinning machine, by filling spin dope, electrostatic spinning and collecting superfine fibre, the aliphatic polyester superfine fibre is prepared, which carries out the adhesive-bonded fabric of electronic spinning nanometre-grade fiber and which can be used as blocking agent after the operation by the decontamination and biocidal treatment. The cloth has good flexibility and toughness, which can overcome the defect of anti-block film reported in the past. Because the degradable materials are selected, the adhesive-bonded fabric begins to degrade after about one month and completely degrade finally, which comes up to the anti-block function.

The present invention relates to hydrogels based on hyaluronic acid based derivatives, that are more resistant than hyaluronic acid alone towards chemical and enzymatic degradation and are endowed with a mix of chemical and mechanical properties such that they are of optimal use in several surgeries, for instance for injection in bone fractures or cavities and for the production of coatings of prostheses in orthopedic surgery, as fillers in cosmetic and maxillo-facial surgery, as anti-adhesion barrier in the prevention of postoperative adhesions in abdominal and abdominal/pelvic surgery, and in general surgery. These hydrogels can be loaded with several different kinds of compounds having pharmacological and biological activity, that are then released from the hydrogel in the site of intervention.

The invention provides a degradable gasket with anti-bacterial anti-adhesion performance. The degradable gasket is prepared via weaving or knitting of a plurality of bundles of magnesium-based metal wire, or via punching of magnesium-based metal sheets. The magnesium-based metal wire can be made of pure magnesium or a magnesium-based alloy of different elements based on disease characteristics and treatment requirements. The degradable gasket possesses excellent biocompatibility; in vivo degradation and absorption can be realized; degradation speed can be controlled; the degradable gasket is capable of preventing postoperative adhesion and infection, and promoting wound healing, can be used for preventing epidural adhesion after orthopedic surgery laminectomy, adhesion after tendon rupture repairing operation, adhesion after knee surgery, dura adhesion after transcranial surgery, eye socket soft tissue adhesion, intestinal adhesion after abdominal surgery, and intrauterine adhesion, is capable of reducing infection risk of the above surgeries, and possesses significant clinical application value.

The present invention is related to the use of benzazole derivatives of formula (I) for the treatment and/or prevention of scleroderma and its therapeutic implications selected in the group consisting of systemic sclerosis, scleroderma-like disoders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloid and other scarring/wound healing abnormalities, postoperative adhesions and reactive fibrosis, as well as chronic heart failure, in particular after myocardial infarction.

The invention belongs to the technical field of biological engineering, and particularly relates to an active cell repairing agent and a preparation method thereof. The active cell repairing agent comprises the following components in percentage by mass: 8-13% of aloe polysaccharide, 6-8% of chitosan oligosaccharide, 4-6% of chitosan, 4-5% of hyaluronic acid, 3-5% of vitamin B5, 2.5-5% of collagen, 2-3% of glutathione, 1-3% of apple polyphenol, 4-8% of octadecanol, 2-5% of albolene, 3-5% of glycerin monostearate, 6-10% of glycerinum, 0.2-0.7% of phenoxyethanol and 23.3-54.3% of water. The active cell repairing agent has the technical advantages that the active cell repairing agent is very good in effect in skin repairing for healing skin injury traumas, reducing cicatrization, reducing postoperative adhesions and the like, free of toxic or side effect and relatively great in clinical application value.

The invention relates to the application of a pharmaceutical composition in the preparation of a drug for treating postoperative adhesions. The pharmaceutical composition uses the extract of Auranthus nudiflora as an active ingredient. The purple bead extract of the naked flower of the invention has a good effect on postoperative adhesion, and has the characteristics of low price, good safety and the like.

The invention relates to an anti-adhesion gel containing polyhydroxyalkanoate and specifically the invention provides an anti-adhesion gel containing hydrophilic organic solvent and polyhydroxyalkanoate. The invention also provides an application of polyhydroxyalkanoate for preparing the medicament used for preventing postoperative adhesions.